| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Nutrien Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$56.11 |
| 52 Week High | CA$75.10 |
| 52 Week Low | CA$48.00 |
| Beta | 0.97 |
| 1 Month Change | 6.35% |
| 3 Month Change | 4.89% |
| 1 Year Change | -22.86% |
| 3 Year Change | 2.13% |
| 5 Year Change | n/a |
| Change since IPO | 3.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NHS | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | 2.9% | -3.4% | -0.01% |
| 1Y | -22.9% | -34.6% | 0.8% |
Rentabilidad frente al sector: 0NHS superó al sector UK Chemicals , que obtuvo un rendimiento del -41.6% el año pasado.
Rentabilidad vs. Mercado: 0NHS obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.3% el año pasado.
Price Volatility
| 0NHS volatility | |
|---|---|
| 0NHS Average Weekly Movement | 4.2% |
| Chemicals Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Precio estable de las acciones: 0NHS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 0NHS (4%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25,900 | Ken Seitz | https://www.nutrien.com |
Nutrien Ltd. suministra insumos y servicios para cultivos. La empresa opera a través de cuatro segmentos: Minorista, Potasa, Nitrógeno y Fosfato. El segmento minorista distribuye nutrientes para cultivos, productos de protección de cultivos, semillas y productos de merchandising.
Nutrien Ltd. Fundamentals Summary
| 0NHS fundamental statistics | |
|---|---|
| Market cap | US$27.61b |
| Earnings (TTM) | US$1.26b |
| Revenue (TTM) | US$28.08b |
21.9x
P/E Ratio1.0x
P/S RatioIs 0NHS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NHS income statement (TTM) | |
|---|---|
| Revenue | US$28.08b |
| Cost of Revenue | US$19.61b |
| Gross Profit | US$8.47b |
| Other Expenses | US$7.22b |
| Earnings | US$1.26b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 2.54 |
| Gross Margin | 30.18% |
| Net Profit Margin | 4.48% |
| Debt/Equity Ratio | 44.6% |
How did 0NHS perform over the long term?
See historical performance and comparison